{"id":"bridging-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bridging chemotherapy is administered before the main curative treatment (typically surgery) to shrink tumors, making them more resectable and potentially improving overall survival. This approach is particularly used in pediatric oncology to allow time for tumor response assessment and to reduce the extent of surgical intervention needed. The specific chemotherapy agents and regimens vary by cancer type and institutional protocols.","oneSentence":"Bridging chemotherapy is a neoadjuvant treatment strategy that uses chemotherapy prior to definitive surgery or other primary therapy to reduce tumor burden and improve surgical outcomes in pediatric cancer patients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:43:22.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric solid tumors requiring neoadjuvant treatment prior to surgery"},{"name":"High-risk pediatric cancers where tumor debulking is clinically indicated"}]},"trialDetails":[{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT05022849","phase":"PHASE1","title":"A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Prostatic Neoplasms","enrollment":15},{"nctId":"NCT06084884","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-14","conditions":"Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT03331198","phase":"PHASE1, PHASE2","title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","status":"RECRUITING","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2017-11-27","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic","enrollment":320},{"nctId":"NCT07443488","phase":"PHASE2","title":"Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-14","conditions":"HSCT, Ph+ ALL","enrollment":20},{"nctId":"NCT07441291","phase":"PHASE3","title":"CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-11-30","conditions":"B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive","enrollment":70},{"nctId":"NCT06267729","phase":"PHASE1, PHASE2","title":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-12","conditions":"Metastatic Prostate Cancer","enrollment":60},{"nctId":"NCT07406724","phase":"PHASE2","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2026-02-26","conditions":"Melanoma (Excluding Uveal Melanoma)","enrollment":90},{"nctId":"NCT03616236","phase":"PHASE3","title":"Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment","status":"SUSPENDED","sponsor":"Friends Research Institute, Inc.","startDate":"2022-07-01","conditions":"Opioid Use","enrollment":320},{"nctId":"NCT06104592","phase":"PHASE2","title":"Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-11-08","conditions":"Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma","enrollment":27},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT07291102","phase":"PHASE3","title":"Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-07-01","conditions":"Medulloblastoma","enrollment":96},{"nctId":"NCT04150913","phase":"PHASE2","title":"A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity","status":"COMPLETED","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2020-10-01","conditions":"Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma","enrollment":15},{"nctId":"NCT07220382","phase":"PHASE4","title":"Preoperative BOTOX® Injection for Large Ventral Hernia Repair","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-11-03","conditions":"Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral","enrollment":188},{"nctId":"NCT05574114","phase":"PHASE1","title":"A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-10-05","conditions":"Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory","enrollment":20},{"nctId":"NCT06090864","phase":"PHASE1, PHASE2","title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-04-25","conditions":"Hodgkin Lymphoma, Relapse, Refractory","enrollment":31},{"nctId":"NCT05621096","phase":"PHASE1","title":"Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2023-03-21","conditions":"DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma","enrollment":33},{"nctId":"NCT07181863","phase":"NA","title":"Technology-Enabled Collaborative Care for Diabetes and Mental Health","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-10","conditions":"Type 2 Diabetes, Mental Health, Diabetes Distress","enrollment":160},{"nctId":"NCT06918834","phase":"PHASE2","title":"Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-07-24","conditions":"Myelodysplastic Syndromes","enrollment":236},{"nctId":"NCT04098146","phase":"","title":"Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis","status":"RECRUITING","sponsor":"AO Innovation Translation Center","startDate":"2022-09-12","conditions":"Mandibular Reconstruction, Segmental Mandibular Defects","enrollment":300},{"nctId":"NCT06912529","phase":"PHASE2","title":"Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma","status":"TERMINATED","sponsor":"Universität Münster","startDate":"2025-03-13","conditions":"B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":1},{"nctId":"NCT06499025","phase":"EARLY_PHASE1","title":"Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)","status":"ENROLLING_BY_INVITATION","sponsor":"BGI, China","startDate":"2024-02-01","conditions":"AML, t(8;21), Neoantigen","enrollment":16},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT05054543","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML","status":"TERMINATED","sponsor":"Apollomics Inc.","startDate":"2021-11-17","conditions":"Relapsed/Refractory AML","enrollment":140},{"nctId":"NCT05664451","phase":"NA","title":"WI-INTUIT: Bridging Community Based Continence Promotion and Primary Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-05-01","conditions":"Urinary Incontinence","enrollment":40},{"nctId":"NCT07022964","phase":"PHASE1, PHASE2","title":"CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-06-01","conditions":"T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)","enrollment":36},{"nctId":"NCT06572631","phase":"PHASE1","title":"Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2025-06-07","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04340167","phase":"PHASE2","title":"Study of Anti-CD22 CAR-T Cells Treating Leukemia Children","status":"COMPLETED","sponsor":"Beijing Boren Hospital","startDate":"2020-05-01","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia","enrollment":14},{"nctId":"NCT04325841","phase":"PHASE2","title":"Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children","status":"COMPLETED","sponsor":"Beijing Boren Hospital","startDate":"2022-03-24","conditions":"Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia","enrollment":2},{"nctId":"NCT06925464","phase":"PHASE1, PHASE2","title":"CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-04-01","conditions":"T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)","enrollment":36},{"nctId":"NCT05347485","phase":"PHASE2","title":"A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2022-05-13","conditions":"Multiple Myeloma","enrollment":86},{"nctId":"NCT06094842","phase":"PHASE1","title":"Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-04-15","conditions":"Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT05870995","phase":"PHASE2","title":"Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-02-01","conditions":"Refractory Leukemia","enrollment":100},{"nctId":"NCT05738408","phase":"NA","title":"Remote Smoking Cessation in Hospitalized Cardiac Patients","status":"RECRUITING","sponsor":"University of Vermont Medical Center","startDate":"2022-08-12","conditions":"Smoking Cessation","enrollment":50},{"nctId":"NCT05588440","phase":"PHASE1, PHASE2","title":"A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies","status":"TERMINATED","sponsor":"Oncternal Therapeutics, Inc","startDate":"2023-05-09","conditions":"Relapsed/Refractory Aggressive B-Cell Malignancies","enrollment":9},{"nctId":"NCT04340154","phase":"PHASE2","title":"Study of Sequential CAR-T Cell Treating Leukemia Children","status":"TERMINATED","sponsor":"Beijing Boren Hospital","startDate":"2020-05-01","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia","enrollment":81},{"nctId":"NCT06646666","phase":"PHASE2","title":"ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-01","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":35},{"nctId":"NCT06567366","phase":"PHASE2","title":"CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09","conditions":"Large B-cell Lymphoma","enrollment":45},{"nctId":"NCT04394650","phase":"PHASE1","title":"A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2020-08-18","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT03610724","phase":"PHASE2","title":"Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-15","conditions":"Non-Hodgkin Lymphoma","enrollment":34},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT03430011","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2018-02-01","conditions":"Multiple Myeloma","enrollment":165},{"nctId":"NCT04231747","phase":"PHASE1","title":"A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2020-05-21","conditions":"Lymphoma Non-Hodgkin, Agressive Lymphoma, Diffuse-large B-cell Lymphoma (DLBCL)","enrollment":24},{"nctId":"NCT06078306","phase":"PHASE2","title":"CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-04-20","conditions":"B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT02445248","phase":"PHASE2","title":"Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-29","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":115},{"nctId":"NCT06224049","phase":"EARLY_PHASE1","title":"Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T","status":"RECRUITING","sponsor":"BGI, China","startDate":"2023-12-01","conditions":"T-cell Lymphoma","enrollment":6},{"nctId":"NCT05370547","phase":"PHASE1, PHASE2","title":"Chidamide Bridging for CAR-T Therapy","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2022-05-25","conditions":"Non Hodgkin's Lymphoma","enrollment":120},{"nctId":"NCT05346198","phase":"PHASE1","title":"Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Shanghai Simnova Biotechnology Co.,Ltd.","startDate":"2021-03-12","conditions":"Multiple Myeloma","enrollment":15},{"nctId":"NCT03677882","phase":"NA","title":"A Brief Mind-Body Bridging Intervention for Suicidal Ideation","status":"TERMINATED","sponsor":"VA Salt Lake City Health Care System","startDate":"2018-12-18","conditions":"Suicidal Ideation, Mind Body Bridging","enrollment":13},{"nctId":"NCT05952986","phase":"PHASE1","title":"A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults","status":"UNKNOWN","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2023-05-03","conditions":"Atopic Dermatitis","enrollment":22},{"nctId":"NCT06182592","phase":"PHASE3","title":"A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2024-01","conditions":"High-risk (Secondary) Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT05929716","phase":"PHASE2","title":"An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-09-30","conditions":"Large B-cell Lymphoma, B-cell Lymphoma","enrollment":""},{"nctId":"NCT03318861","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Kite, A Gilead Company","startDate":"2017-10-20","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":17},{"nctId":"NCT05871684","phase":"PHASE2","title":"A Combination Study of CAR-T Therapy in r/r B-NHL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2023-06-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":48},{"nctId":"NCT05930262","phase":"NA","title":"Acupuncture Therapy Combined With Breathing Training for Patients With Stroke Complicated","status":"COMPLETED","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2020-05-01","conditions":"Stroke, Lung Diseases","enrollment":72},{"nctId":"NCT04161118","phase":"PHASE2","title":"TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"University of Cologne","startDate":"2021-05-12","conditions":"Non Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT05393635","phase":"PHASE1","title":"ITIL-168 in Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"Instil Bio","startDate":"2022-08","conditions":"Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT05651100","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma","status":"UNKNOWN","sponsor":"Kecellitics Biotech Company Ltd","startDate":"2022-12-10","conditions":"Lymphoma, B-Cell","enrollment":50},{"nctId":"NCT04037241","phase":"PHASE2, PHASE3","title":"Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases","status":"WITHDRAWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2021-11-01","conditions":"Malignant Tumor of Pancreas Metastatic to Liver","enrollment":""},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT04677452","phase":"PHASE1","title":"Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-12","conditions":"Safety and Efficacy","enrollment":24},{"nctId":"NCT02734862","phase":"PHASE2","title":"CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension","status":"COMPLETED","sponsor":"Cidara Therapeutics Inc.","startDate":"2016-07-26","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":207},{"nctId":"NCT03628053","phase":"PHASE3","title":"Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-05","conditions":"Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT02904213","phase":"NA","title":"Evaluate Safety of ComBe Five (Liquid) in Healthy Vietnamese Children Aged From 8 - 10 Weeks as a 3-dose Series, Interval for Each Dose is 4 Weeks","status":"COMPLETED","sponsor":"Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products","startDate":"2016-09-16","conditions":"Safety, Pentavalent Vaccine","enrollment":330},{"nctId":"NCT02846584","phase":"PHASE2","title":"a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies","status":"UNKNOWN","sponsor":"Southwest Hospital, China","startDate":"2016-07","conditions":"Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma，Malignant","enrollment":100},{"nctId":"NCT01840943","phase":"PHASE3","title":"A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy","status":"TERMINATED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2013-06","conditions":"Epithelial Ovarian Cancer","enrollment":32},{"nctId":"NCT01055301","phase":"PHASE2","title":"S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2011-07","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT02141698","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Dose Finding Study","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bridging Chemotherapy","genericName":"Bridging Chemotherapy","companyName":"Nationwide Children's Hospital","companyId":"nationwide-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bridging chemotherapy is a neoadjuvant treatment strategy that uses chemotherapy prior to definitive surgery or other primary therapy to reduce tumor burden and improve surgical outcomes in pediatric cancer patients. Used for Pediatric solid tumors requiring neoadjuvant treatment prior to surgery, High-risk pediatric cancers where tumor debulking is clinically indicated.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}